Drug Search Results
More Filters [+]

Tofimilast

Alternative Names: tofimilast
Latest Update: 2012-11-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PDE4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tofimilast

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Chronic Obstructive Pulmonary Disease|Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A2641021

P2

Completed

Asthma

2005-11-01

A2641022

P2

Completed

Chronic Obstructive Pulmonary Disease

2005-07-01

Recent News Events

Date

Type

Title